Savant HWP Inc.
Aiming to interrupt addictions, at a basic level
This article was originally published in Start Up
Executive Summary
The founders of Savant HWP Inc. believe they have identified a molecule that could prove effective in treating many kinds of substance as well as behavioral addictions, because it appears to influence relevant brain chemistry at a fundamental level. Its compound binds to the alpha-3-beta-4 nicotinic acetylcholine receptor and appears to indirectly regulate production of dopamine in the mid-brain.
You may also be interested in...
Best Of BIO: Policy & Regulatory Updates From BIO 2017
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.